Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with bortezomib may kill more cancer cells. It is not yet known whether combination chemotherapy is more effective with or without bortezomib in treating mantle cell lymphoma.
PURPOSE: This randomized phase II trial is studying combination chemotherapy and bortezomib to see how well they work compared with combination chemotherapy alone in treating patients with relapsed or refractory mantle cell lymphoma. Combination chemotherapy alone (Arm I) has been discontinued April 2012 on recommendation of the DMC.
연구 개요
상태
정황
상세 설명
OBJECTIVES:
Primary
- To evaluate the rates of overall response (complete response [CR], CR unconfirmed [CRu], and partial response).
Secondary
- To evaluate the rates of CR and CRu.
- To determine the median time to progression.
- To determine the median overall survival.
- To evaluate the toxicity and tolerability.
- To compare the responses to these treatment regimens with those from first line therapy.
- To compare the quality of life.
OUTLINE: This is a randomized, open-label, parallel group, multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I (CHOP): Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1 and oral prednisolone on days 1-5. Arm I has been discontinued April 2012 on recommendation of the DMC.
- Arm II (CHOP with bortezomib): Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5.
In both arms, treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment.
After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
England
-
Basingstoke, England, 영국, RG24 9NA
- Basingstoke and North Hampshire NHS Foundation Trust
-
Birmingham, England, 영국, B9 5SS
- Birmingham Heartlands Hospital
-
Birmingham, England, 영국, B75 7RR
- Good Hope Hospital
-
Blackpool, England, 영국, FY3 8NR
- Blackpool Victoria Hospital
-
Cambridge, England, 영국, CB2 2QQ
- Addenbrooke's Hospital
-
Dartford, England, 영국, DA2 8DA
- Darent Valley Hospital
-
Harrogate, England, 영국, HG2 7SX
- Harrogate District Hospital
-
Leeds, England, 영국, LS1 3EX
- Leeds General Infirmary
-
Liverpool, England, 영국, L7 8XP
- Royal Liverpool University Hospital
-
London, England, 영국, SE1 9RT
- Guy's Hospital
-
Maidstone, England, 영국, ME16 9QQ
- Mid Kent Oncology Centre at Maidstone Hospital
-
Newcastle-Upon-Tyne, England, 영국, NE1 4LP
- Royal Victoria Infirmary
-
Norfolk, England, 영국, NR31 6LA
- James Paget Hospital
-
Norwich, England, 영국, NR4 7UY
- Norfolk and Norwich University Hospital
-
Plymouth, England, 영국, PL6 8DH
- Derriford Hospital
-
Prescot Merseyside, England, 영국, L35 5DR
- Whiston Hospital
-
Southampton, England, 영국, SO16 6YD
- Southampton General Hospital
-
Sunderland, England, 영국, SR4 7TP
- Sunderland Royal Hospital
-
Taunton, England, 영국, TA1 5DA
- Musgrove Park Hospital
-
Torquay, England, 영국, TQ2 7AA
- Torbay Hospital
-
Truro, Cornwall, England, 영국, TR1 3LJ
- Royal Cornwall Hospital
-
-
Scotland
-
Aberdeen, Scotland, 영국, AB25 2ZN
- Aberdeen Royal Infirmary
-
Inverness, Scotland, 영국, 1V2 3UJ
- Raigmore Hospital
-
-
Wales
-
Bangor, Wales, 영국, LL57 2PW
- Ysbyty Gwynedd
-
Llanelli, Wales, 영국, SA14 8QF
- Prince Philip Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Diagnosis of mantle cell lymphoma (MCL)
- Expression of cyclin D1 or evidence of t(11;14) translocation by cytogenetics, FISH, or polymerase chain reaction
- Refractory to or relapsed or progressed after first line antineoplastic therapy
- Measurable disease
PATIENT CHARACTERISTICS:
Inclusion criteria:
- Karnofsky performance status (PS) 50-100% OR ECOG PS 0-2
- ANC ≥ 1,000/mm³ (not related to lymphoma)
- Platelet count ≥ 30,000/mm³
- AST and ALT ≤ 3 times upper limit of normal (ULN)
- Total bilirubin ≤ 2 times ULN
- Creatinine clearance ≥ 20 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
Exclusion criteria:
- Known serological positivity for HBV, HCV, or HIV
- History of allergic reaction attributable to compounds containing boron or mannitol
- Diagnosed or treated for a malignancy other than MCL within the past 5 years except for completely resected basal cell or squamous cell carcinoma of the skin or any in situ malignancy
- Active systemic infection requiring treatment
- Serious medical or psychiatric illness that would preclude study participation
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- Toxic effects of prior therapy or surgery must be resolved to ≤ grade 2
- Prior splenectomy or localized radiotherapy allowed
Any prior chemotherapy regimen allowed
- Chemotherapy may have been given in combination with rituximab
- Concurrent enrollment in a nontreatment study allowed, provided it does not interfere with participation in this study
Exclusion criteria:
- Prior bortezomib
- Antineoplastic therapy within the past 3 weeks
- Nitrosoureas within the past 6 weeks
- Rituximab, alemtuzumab (Campath®), or other unconjugated therapeutic antibody within the past 4 weeks
- Radiotherapy within the past 3 weeks
- Major surgery within the past 2 weeks
- Concurrent investigational agents
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Bortezomib plus CHOP
Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment. After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Disease progression
기간: 30 days and every 12 weeks
|
The follow-up visits will be at 30 days after last dose of study drug and after that every 12 weeks until: Progressive disease, initiation of further anti-neoplastic therapy, patient decision to withdraw from the study, patient death.
|
30 days and every 12 weeks
|
|
Unacceptable toxicity or tolerability as assessed by NCI CTCAE v3.0
기간: continual after first drug dose
|
The follow-up visits will be at 30 days after last dose of study drug and after that every 12 weeks until: Progressive disease, initiation of further anti-neoplastic therapy, patient decision to withdraw from the study, patient death.
|
continual after first drug dose
|
공동 작업자 및 조사자
수사관
- 연구 의자: Simon Rule, MD, Derriford Hospital
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 신생물
- 림프 증식 장애
- 림프계 질환
- 면역증식성 장애
- 림프종, 비호지킨
- 림프종
- 림프종, 외투세포
- 약물의 생리적 효과
- 약리작용의 분자기전
- 효소 억제제
- 항염증제
- 항류마티스제
- 항종양제
- 면역억제제
- 면역학적 요인
- 튜불린 조절제
- 항유사분열제
- 유사분열 조절제
- 글루코 코르티코이드
- 호르몬
- 호르몬, 호르몬 대체물 및 호르몬 길항제
- 항종양제, 호르몬
- 항종양제, 알킬화제
- 알킬화제
- 골수 파괴 작용제
- 항종양제, 식물성
- 토포이소머라제 II 억제제
- 토포이소머라제 억제제
- 항생제, 항종양제
- 프레드니솔론
- 사이클로포스파마이드
- 보르테조밉
- 독소루비신
- 리포솜 독소루비신
- 빈크리스틴
기타 연구 ID 번호
- CDR0000559820
- NCRN-Ply-26s
- EU-20747
- ISRCTN200600609024
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .